GONAL - F 75 IU (5.5 microgram/Vial) Price

Overview

Welcome to Dwaey, specifically on GONAL - F 75 IU (5.5 microgram/Vial) Injection/Powder for page.
This medicine contains an important and useful components, as it consists of Follitropin alfa (r-human FSH).
GONAL - F 75 IU (5.5 microgram/Vial) is available in the market in concentration 5.5mcg/Vial and in the form of Injection/Powder for.

MERCK EUROPE B V is the producer of GONAL - F 75 IU (5.5 microgram/Vial) and it is imported from NETHERLANDS, The most popular alternatives of GONAL - F 75 IU (5.5 microgram/Vial) are listed downward .

Mode Of Action

Follitropin alfa is a human FSH preparation of recombinant DNA origin. It stimulates ovarian follicular growth in women who do not have primary ovarian failure and stimulates spermatogenesis in men with hypogonadotrophic hypogonadism.

Indication

• Female infertility
• Assisted reproductive technologies
• Spermatogenesis induction

Precaution

May result in multiple births. Ovarian hyperstimulation syndrome, serious pulmonary conditions and thromboembolic events may occur. Evaluate patients for hypothyroidism, adrenocortical deficiency, hyperprolactinaemia, pituitary and hypothalamic tumors before starting therapy. Lactation: Excretion in milk unknown; not recommended

Side Effects

• Ovarian cysts
• mild to severe Inj site reactions
• headache
• mild to moderate ovarian hyperstimulation syndrome (OHSS)
• abdominal pain
• GI disturbances. Rarely
• severe OHSS
• ovarian torsion
• thromboembolism
• mild systemic allergic reactions.

Contra indication

Hypersensitivity. Abnormal genital bleeding of undetermined origin, sex hormone sensitive malignancies of the reproductive tract and accessory organs, an organic intracranial lesion e.g. pituitary tumor, ovarian cysts or enlargement of undetermined origin, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, pregnancy, lactation.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.